[DRRX] DURECT Corporation


Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization: 195.05 M

Exchange: NASDAQ

The data is delayed by 15 minutes.


Price: 1.28 Change: 0.04 (3.23%)
Ext. hours: Change: 0 (0%)

chart DRRX

Refresh chart

Strongest Trends Summary For DRRX

DRRX is in the medium-term up 37% in 1 month and down -65% below S&P in 1 year. In the long-term down -74% below S&P in 5 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart


Description: DURECT Corporation, a specialty pharmaceutical company, is engaged in the development of pharmaceutical products based on its proprietary drug delivery technology platforms in the United States and internationally. It focuses on the development of various products for the treatment of various chronic and episodic disease areas, such as pain, central nervous system disorders, metabolic disorders, cardiovascular disease, and other chronic diseases. The company?s products comprise ALZET product line that consists of osmotic pumps and accessories, which are used for experimental research in mice, rats, and other laboratory animals; and a range of standard and custom biodegradable polymers that are used as raw materials in the pharmaceutical and medical devices under the brand name of LACTEL. Its products also include REMOXY, an oral oxycodone gelatin capsule for chronic pain; POSIDUR, a formulation of bupivacaine for the treatment of post-surgical pain that has completed Phase III clinical study; ELADUR, a Phase

Fundamental Ratios
Shares Outstanding137.36 M EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters 4.19% Sales Growth - Q/Q11.81% P/E
P/E To EPS Growth P/S10.91 P/BV12.6 Price/Cash Per Share6.72
Price/Free Cash Flow-13.53 ROA-51.33% ROE-150.97% ROI-65.53%
Current Ratio5.02 Quick Ratio4.5 Long Term Debt/Equity0.62 Debt Ratio0.47
Gross Margin68.52% Operating Margin-122.01% Net Profit Margin-130.66% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities240 K Cash From Investing Activities4.42 M Cash From Operating Activities-5.35 M Gross Profit3.77 M
Net Profit-4.85 M Operating Profit-4.42 M Total Assets45.52 M Total Current Assets36.47 M
Total Current Liabilities7.26 M Total Debt19.84 M Total Liabilities30.04 M Total Revenue4.77 M
Technical Data
High 52 week2.51 Low 52 week0.48 Last close0.78 Last change-0.47%
RSI73.09 Average true range0.05 Beta1.38 Volume369.5 K
Simple moving average 20 days17.09% Simple moving average 50 days24.9% Simple moving average 200 days-33.79%
Performance Data
Performance Week5.62% Performance Month32.27% Performance Quart-5.83% Performance Half-40.34%
Performance Year-30.21% Performance Year-to-date61.79% Volatility daily4.09% Volatility weekly9.15%
Volatility monthly18.75% Volatility yearly64.94% Relative Volume282.28% Average Volume409.51 K
New High New Low


2019-03-21 08:00:00 | DURECT Announces Patient Dosing in Phase 2a Proof-of-Concept Clinical Trial of Topical DUR-928 in Patients with Mild to Moderate Plaque Psoriasis

2019-03-13 16:00:00 | DRRX: DUR-928 Programs Accelerating. Anticipate NASH, Psoriasis Data Later This Year

2019-03-08 22:43:02 | Edited Transcript of DRRX earnings conference call or presentation 7-Mar-19 9:30pm GMT

2019-03-08 21:48:14 | Durect Corp DRRX Files 10-K for the Fiscal Year Ended on December 31, 2018

2019-03-07 16:05:00 | DURECT Corporation Announces Fourth Quarter and Full Year 2018 Financial Results and Update of Programs

2019-03-04 08:00:00 | DURECT Corporation Invites You to Join its Fourth Quarter 2018 Earnings Conference Call

2019-02-27 07:00:00 | DURECT Announces Plans to Submit to FDA a Full Response to the POSIMIR® Complete Response Letter

2019-02-26 12:00:12 | DURECT Corporation NASDAQ:DRRX: Time For A Financial Health Check

2019-02-22 07:20:00 | Factors of Influence in 2019, Key Indicators and Opportunity within ARRIS International plc, Edwards Lifesciences, DENTSPLY SIRONA, Vail Resorts, Akers Biosciences, and DURECT — New Research Emphasizes Economic Growth

2019-02-21 08:00:00 | DURECT Corporation to Participate in the Berenberg NASH Day

2019-01-24 07:00:00 | Streetwise Reports Examines the Commercial Launch Planned for Schizophrenia Drug

2019-01-11 11:45:00 | DRRX: Pipeline Update: Focus Is On Accelerating DUR-928 in NASH and Other High-Potential Indications

2019-01-07 07:30:00 | DURECT Corporation Provides Corporate Update

2019-01-04 06:59:02 | Here’s What We Think About DURECT Corporation’s NASDAQ:DRRX CEO Pay

2019-01-03 16:30:00 | DURECT Corporation Announces Investor Call to Provide Corporate Update

2018-12-19 08:00:00 | Commercial Launch Plans Announced for PERSERIS™ risperidone Extended-Release Injectable Suspension for the Treatment of Schizophrenia in Adults

2018-12-17 08:00:00 | DURECT Corporation Announces Retirement of Dr. Felix Theeuwes as Chairman of the Board and Distinguished Scientist

2018-11-30 07:55:00 | Analysis: Positioning to Benefit within News Corporation, DURECT, Ecolab, MiX Telematics, Ship Finance International, and BCE — Research Highlights Growth, Revenue, and Consolidated Results

2018-11-19 08:00:00 | DURECT Announces Amendment to Accelerate Ongoing Phase 2a Trial of DUR-928 in Alcoholic Hepatitis AH by Allowing Dosing of Severe AH Patients in Parallel to Moderate AH Patients

2018-11-16 14:30:00 | DRRX: Protocol Amendment Speeds DUR-928 Ph2 AH Trial. PERSERIS FDA Approval Adds New Revenue Stream

2018-11-13 13:44:00 | Could DURECT Corporation’s NASDAQ:DRRX Investor Composition Influence The Stock Price?

2018-11-09 03:17:05 | Edited Transcript of DRRX earnings conference call or presentation 7-Nov-18 9:30pm GMT

2018-11-07 17:13:14 | Durect: 3Q Earnings Snapshot

2018-11-07 16:01:00 | DURECT Corporation Announces Third Quarter 2018 Financial Results and Provides Corporate Update

2018-11-01 16:15:00 | DURECT Corporation Invites You to Join its Third Quarter 2018 Earnings Conference Call

2018-10-25 08:00:00 | DURECT Announces Abstracts on DUR-928 to be Presented at Upcoming Scientific Meetings

2018-10-23 08:20:00 | Report: Exploring Fundamental Drivers Behind Alder BioPharmaceuticals, DURECT, Mettler-Toledo International, Internap, Career Education, and Approach Resources — New Horizons, Emerging Trends, and Upcoming Developments

2018-10-01 08:00:00 | DURECT Corporation Appoints Michael H. Arenberg, J.D., M.B.A. as Chief Financial Officer

2018-09-25 08:00:00 | DURECT to Present at the Cantor Fitzgerald Global Healthcare Conference

2018-09-19 12:50:42 | Is DURECT Corporation’s NASDAQ:DRRX Balance Sheet Strong Enough To Weather A Storm?

2018-09-18 08:00:00 | DURECT Announces Methydur Sustained Release Capsules Receive Marketing Authorization for ADHD in Taiwan

2018-08-30 08:00:00 | DURECT Announces Receipt of $5 Million Milestone Payment from Indivior

2018-08-27 16:30:00 | DURECT to Present at the 20th Annual Rodman & Renshaw Global Investment Conference

2018-08-21 07:45:00 | Recent Analysis Shows DURECT, Corporacion America Airports S.A., Golden Star Resources, MacroGenics, Merus N.V., and Superior Uniform Group Market Influences — Renewed Outlook, Key Drivers of Growth

2018-08-06 15:32:14 | FDA Decision Sends Pain Therapeutics Reeling

2018-08-06 09:22:00 | DURECT's Licensee Pain Therapeutics Receives Complete Response Letter from FDA for REMOXY® ER oxycodone Extended-Release Capsules CII

2018-08-01 21:14:22 | Edited Transcript of DRRX earnings conference call or presentation 1-Aug-18 8:30pm GMT

2018-08-01 17:42:47 | Durect: 2Q Earnings Snapshot

2018-08-01 16:05:00 | DURECT Corporation Announces Second Quarter 2018 Financial Results and Provides Corporate Update

2018-07-30 11:42:00 | Why Durect Corporation Stock Is Spiking Today

2018-07-30 08:00:00 | DURECT Announces FDA Approval of Indivior's PERSERIS™ risperidone Extended-Release Injectable Suspension for the Treatment of Schizophrenia in Adults

2018-07-24 16:05:00 | DURECT Corporation Invites You to Join its Second Quarter 2018 Earnings Conference Call

2018-07-22 17:03:40 | The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Results, Earnings And IPOs

2018-07-09 07:25:00 | Complimentary Technical Snapshots on Teva Pharma Industries and Three More Drug Makers Stocks

2018-07-05 12:25:46 | A Look At Biotech In 2018 And The Biggest Catalysts Coming Up In The Second Half Of The Year

2018-06-30 18:05:47 | Attention Biotech Investors: Mark Your Calendar For These July PDUFA Dates

2018-06-28 15:48:07 | Pain, Durect Plunge as FDA Committee Votes Against Remoxy ER

2018-06-27 13:29:00 | Here's Why Drug Developer DURECT Corporation Plunged Today

2018-06-27 08:14:48 | Benzinga's Daily Biotech Pulse: Pain Therapeutics Drops 70%, Neon To Begin Trading

2018-06-26 20:30:00 | Results of FDA Advisory Committee Meeting for REMOXY® ER